Santhera Pharmaceuticals Holding AG
F:S3F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Santhera Pharmaceuticals Holding AG
F:S3F
|
CH |
|
DRDGOLD Ltd
F:DUB1
|
ZA |
|
Koninklijke Philips NV
F:PHI1
|
NL |
|
S
|
System1 Group PLC
F:BBA
|
UK |
|
Unicharm Corp
OTC:UNCHF
|
JP |
Wall St Price Targets
S3F Price Targets Summary
Santhera Pharmaceuticals Holding AG
According to Wall Street analysts, the average 1-year price target for S3F is 23.91 EUR with a low forecast of 21.53 EUR and a high forecast of 26.85 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S3F's stock price target?
Price Target
23.91
EUR
According to Wall Street analysts, the average 1-year price target for S3F is 23.91 EUR with a low forecast of 21.53 EUR and a high forecast of 26.85 EUR.
What is the Revenue forecast for Santhera Pharmaceuticals Holding AG?
Projected CAGR
49%
Over the last 13 years, the compound annual growth rate for Revenue has been 21%. The projected CAGR for the next 3 years is 49%.
What is the Gross Profit forecast for Santhera Pharmaceuticals Holding AG?
Projected CAGR
-19%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 4 years is -19%.
